<DOC>
	<DOCNO>NCT01014429</DOCNO>
	<brief_summary>The purpose study evaluate safety tolerability NMS-1286937 , polo-like-kinase 1 inhibitor , patient advance metastatic solid tumor .</brief_summary>
	<brief_title>Study NMS-1286937 Adult Patients With Advanced/Metastatic Solid Tumors</brief_title>
	<detailed_description />
	<criteria>Advanced/metastatic solid tumor , effective standard therapy exist Adult patient ( age &gt; /= 18 ) ECOG performance status ( PS ) 0 1 Life expectancy least 3 month Adequate renal , liver function bone marrow reserve Prior cancer therapy allow , max 4 regimen chemotherapy . Washout : least 4 wks ( 6 wks nitrosoureas , mitomycin C liposomal doxorubicin ) toxicity recover CTC Grade &lt; /=1 Prior radiotherapy allow 25 % BM reserve irradiate Women men child produce potential agree use effective contraception Capability swallow capsule intact Known uncontrolled/symptomatic brain metastasis Currently active second malignancy Major surgery last 4 wks Any follow past 6 month : myocardial infarction , unstable angina , coronary/peripheral artery bypass graft , symptomatic congestive heart failure , cerebrovascular accident transient ischemic attack , pulmonary embolism , deep vein thrombosis Pregnancy breastfeed woman Known active infection History drug allergic reaction Gastrointestinal disease malabsorption syndrome would impact drug absorption . Documented gastrointestinal ulcer Other severe concurrent acute chronic medical psychiatric condition could compromise protocol objective</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>September 2012</verification_date>
	<keyword>Phase I dose escalation study</keyword>
	<keyword>Advanced metastatic solid tumor</keyword>
	<keyword>PLK 1 inhibitor</keyword>
	<keyword>Adult patient</keyword>
</DOC>